Will Gilead's Remdesivir Only Be a Short-Lived Success Story?
It's rare that an FDA-approved drug is known more by its generic name than its brand name. It's also rare that a drug receives widespread publicity well before it reaches the market. Both scenarios, however, apply to Gilead Sciences' (NASDAQ: GILD) remdesivir, which is marketed under the brand name Veklury.
Remdesivir generated sales of $873 million in the third quarter, its first full quarter on the market. There's no question whatsoever that Gilead's COVID-19 drug will become the big biotech's newest blockbuster in Q4. But will the success story for remdesivir only a be short-lived one?
Image source: Getty Images.
Source Fool.com
